Chester County News and Community Website
WILMINGTON, DE — Incyte (Nasdaq: INCY) is set to present pivotal data from its hematology/oncology portfolio at the 2025 European Hematology Association (EHA) Congress, scheduled for June 12–15 in Milan. …
Incyte to Showcase Groundbreaking Hematology/Oncology Data at EHA 2025 Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced its participation in the Goldman Sachs Healthcare Conference, scheduled for Monday, June 9, 2025, at 11:20 AM (ET).
Incyte to Present Live at Goldman Sachs Healthcare Conference 2025 Read More WILMINGTON, DE — A new treatment option has emerged for patients battling advanced squamous cell carcinoma of the anal canal (SCAC). The U.S. Food and Drug Administration (FDA) has approved …
FDA Approves Zynyz for Advanced Anal Cancer, Offering New Hope for Patients Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced it granted restricted stock unit awards (RSUs) totaling 33,413 shares of common stock and stock options to purchase 8,951 shares to 60 new …
Incyte Announces New Employee Stock Awards Under 2024 Inducement Plan Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced its participation in the 2025 BofA Securities Health Care Conference. The company’s presentation is scheduled for Tuesday, May 13, 2025, at 1:40 PM …
Incyte to Present at 2025 BofA Securities Health Care Conference Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) delivered strong first-quarter financial results for 2025, propelled by revenue growth across its key products and continued advances in its clinical portfolio. Total revenues …
Incyte Reports Strong Q1 2025 Financial Results and Pipeline Progress Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has announced that multiple abstracts highlighting data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual …
Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting Read More WILMINGTON, DE — Biopharmaceutical company Incyte (Nasdaq: INCY) recently awarded restricted stock units (RSUs) totaling 20,334 shares of common stock to 24 newly hired employees. These awards were granted as …
Incyte Grants Restricted Stock Units to New Employees Read More WILMINGTON, DE — Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for moderate to severe hidradenitis suppurativa …
Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced its expansion in Delaware with the acquisition of two buildings in downtown Wilmington. Located at 1100 North King Street and 1100 North French …
Incyte Expands Delaware Presence with New Wilmington Buildings Read More